SEC Form 4 · accession 0001140361-17-037214
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Baffi
Officer — EVP, Technical Operations
Period of report
Sep 28, 2017
Accepted (ET)
Oct 2, 2017 · 9:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 28, 2017 | S | 15,500 | $92.4952 | D | 129,083 | D | |
| Common StockF1,F3 | Sep 28, 2017 | S | 2,915 | $92.06 | D | 28,761 | I | Shares held by Baffi Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on September 12, 2017.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $91.92 to $92.90. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3All shares sold at the same price.